Mavatar announces research collaboration with Sobi
Esme Needham | January 6, 2026 | News story | Research and Development | Immunology, Mavatar, Rare Diseases, sobi
Mavatar has announced the initiation of a non-clinical research collaboration with Sobi, using Mavatar’s technology to generate data insights into disease.
Sobi is a global biopharmaceutical company specialising in rare diseases. Mavatar is a company focused on precision medicine driven by AI and data analytics.
Mavatar will use its Mavatar Discovery analysis platform, designed to combine and contextualise transcriptomic data sets, to research interferon gamma (IFNγ)-associated biological pathways. By exploring how IFNγ-related molecular patterns present themselves in certain data sets, the two companies hope to contribute to research on immune-mediated and rare diseases.
Mavatar Discovery is enabled by Mavatar’s proprietary Deep Integrated Network Analysis (DINA) technology. Its goal is to combine publicly available data with biologically meaningful networks, providing insights for researchers in fields such as academia, pharmaceuticals and biotechnology.
The project will build on Mavatar’s existing research in the areas of rare disease and immunology. These areas have been identified as particularly fruitful for AI- and data-driven research.
Johan Juhlin, co-founder and CEO of Mavatar, said Sobi’s “deep commitment to rare diseases aligns strongly with our mission. Through advanced analytics of public transcriptomic data, we aim to contribute to a clearer understanding of IFNγ-driven mechanisms across relevant biological contexts.”
“Understanding the underlying biology of rare and immune-mediated conditions is essential for advancing research in the field,” added Emmanuel Monet, head medical science strategy at Sobi. “Through this collaboration, we aim to further strengthen our scientific knowledge base using structured, data-driven analyses.”
Related Content
FDA approves Gamifant for macrophage activation syndrome in Still’s disease
The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of …
Sobi and Sanofi’s Foundation S renew partnership with World Federation of Hemophilia
Sobi and Sanofi, through its organisation Foundation S, have extended their partnership with the World …
EC grants marketing authorisation to Sobi’s Altuvoct for haemophilia A treatment
Sobi has announced that the European Commission (EC) has granted marketing authorisation for Altuvoct (efanesoctocog …
